

Diagnostics Advisory Committee Interests Register – Standing Committee Members

Topic: FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Alasdair Taylor	Standing committee member	Indirect	Elected member of the council of the Royal college of Radiologists, representing the faculty of clinical radiology	Sept 2020	August 2021	Ongoing	<i>Declare and participate, Chair, October 201</i>
Alexandria Moseley	Standing committee member	None	-	-	-	-	
Brian Shine	Standing committee member	None	-	-	-	-	
Brendan Meyer	Standing committee member	None	-	-	-	-	
Diane Davies	Standing committee member	None	-	-	-	-	
John Cairns	Standing committee member	Financial	Advising Astellas on economic evaluation of roxadustat Advising Takeda on economic evaluation of maribavir	Nov 2020 August 2021	Nov 2021	May 2021 August 2021	<i>Declare and participate, Chair 6 December 2021</i>
Joy Allen	Standing committee member	Financial	Employee of Roche Diagnostics UK & Ireland	August 2021	March 2022		<i>Declare and participate, Chair 15 March 2022</i>
Joy Allen	Standing committee member	Non-financial professional and personal interests	My employer, Roche, manufactures the commercially available Elecsys® GAAD test for the aid in diagnosis of early-stage HCC.		March 2022		<i>Declare and participate, Chair 21 March 2022</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Joy Allen	Standing committee member	Non-financial professional and personal interests	Guest Researcher status, Newcastle University for collaborations with the NIHR In Vitro Diagnostics Co-operative on diagnostic test evaluation methodology	August 2021	March 2022		<i>Declare and participate, Chair 15 March 2022</i>
Joy Allen	Standing committee member	Non-financial professional and personal interests	I am co-author on a number of publications describing evaluation of diagnostic test evaluations, some of which include commercially supplied tests. All evaluations which I undertook during my time at the NIHR Diagnostic Evidence Co-operative and more recently at the Newcastle In Vitro Diagnostics Co-operative were independent investigator initiated studies.	September 2014	March 2022	31 August 2021	<i>Declare and participate, Chair 15 March 2022</i>
Joy Allen	Standing committee member	Non-financial professional and personal interests	<p>Range of funding as co-applicant or PI in my previous roles:</p> <p>Co-applicant on NIHR i4i Connect Award: 'GlycoScore: Superior prostate cancer diagnosis using a simple blood test'. Role: Lead on the care pathway analysis and early economic modelling studies. Feb 2021 – April 2022. Award Value: £150K</p> <p>Co-Investigator on UKRI funded 'COVID-19 National Diagnostic Research and Evaluation platform (CONDOR)'. This study is on the Urgent Public Health Portfolio. Role:</p>	May 2017	March 2022	August 2021	<i>Declare and participate, Chair 15 March 2022</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			<p>Lead the Care Pathway Analysis workstream. May 2020- June 2021. Award Value: £1.3m</p> <p>Co-applicant on NIHR Product Development Award 'Development of RxSelex: A microbiome-based predictive diagnostic of IBD biologics treatment outcome'. Role: Lead on barriers to adoptions studies. . Jan 2019 – Aug 2021 Award value: £1.2m</p> <p>Co-applicant on MRC CIC funded 'GlycoScore: Validation of a non-invasive diagnostic test to distinguish benign and aggressive prostate cancer' Role: Lead Early feasibility pathway studies. Jan 2020 – Sept 2020. Award Value: £80K</p> <p>Co-applicant on HTA commissioned call entitled 'Primary care management of lower urinary tract symptoms in men: Development and validation of a diagnostic and decision-making aid (The PriMUS Study)'. Lead in the development of the prototype decision aid and mathematically modelling the effect of the tool on secondary care referral rates. May 2017 – April 2020. Award value: ~£1.56m</p> <p>Co-applicant on HTA commissioned call entitled 'Antifungal stewardship opportunities with rapid tests: The A-Stop Study'. Role: Lead on novel statistical analyses to overcome imperfect reference standard. April 2017 – March 2021. Award value: ~£1.5m</p>				

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Karen Sennett	Standing committee member	None	-	-	-	-	
Keith Abrams	Standing committee member	Financial	Partner & Director, Visible Analytics Limited - a HTA Consultancy company, but I have not been involved in any projects which involve a diagnostic technology. However, Visible Analytics is undertaking a project for Echoscens on evaluating FibroScan for assessing liver fibrosis and cirrhosis in primary care. I am not involved in the project in any way and measures have been taken (for example I do not have access to the project folder etc) to avoid potential conflicts.	May 2019	16 Feb 2022	Ongoing	<i>Exclude from discussions, Chair and AD, 21 February 2022</i>
Liz Adair	Standing committee member	None	-	-	-	-	
Matt Stevenson	Standing committee member	Non-financial professional and personal interests	I undertook the pilot Diagnostics topic, which included FibroScan for the detection of liver fibrosis in patients with suspected alcohol-related liver disease. This work was published as an HTA monograph. Health Technology Assessment 2012 (16) 4. This concluded that further data was needed before a robust estimate of the cost-effectiveness could be made.		5 Nov 2021	Dec 2012	<i>Declare and participate, Chair 6 December 2021</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Messenger	Standing committee member	Non-financial professional and personal interests	Siemens Healthineers and iQUR- I have previously conducted and published NIHR funded research on the Siemens/iQUR Enhanced Liver Fibrosis test.	16/08/2009	Dec 2021	01/10/2020	<i>Declare and participate, Chair 6 December 2021</i>
Neil Hawkins	Standing committee member	Financial	I am a director of an HTA consultancy providing consultancy services to Echosens. I have no personal involvement in the provision of these services	March 2021	7 Nov 2021	Ongoing	<i>Due to this conflict of interest, Neil Hawkins has excused himself from this topic.</i>
Patrick McGinley	Standing committee member	Financial	Faculty Membership of MedTech Access. Honorarium received for advising on NHS finance flows	April 2020	July 2021	Ongoing	<i>Declare and participate, Chair, October 2021</i>
Patrick McGinley	Standing committee member	Non-financial personal and professional interests	Hon. Treasurer of Association for the Study of Obesity	Sept 2019	July 2021	Ongoing	<i>Declare and participate, Chair, October 2021</i>
Patrick McGinley	Standing committee member	Non-financial personal and professional interests	Member of Strategic Council for the All Party Parliamentary Group on Obesity	Oct 2019	July 2021	Ongoing	<i>Declare and participate, Chair, October 2021</i>
Radha Ramachandran	Standing committee member	None	-	-	-	-	
Rebecca Allcock	Standing committee member	None	-	-	-	-	

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Sam Creavin	Standing committee member	None	-	-	-	-	
Stephen Habgood	Standing committee member	Non-financial personal and professional interests	I am a member of the NICE Medical Technology Advisory Group.	2019	Jan 2022	ongoing	<i>Declare and participate, Chair, Jan 2022</i>
Stephen Habgood	Standing committee member	Non-financial personal and professional interests	I am Director of a Community Interest Company – ‘Making Families Count’. This group delivers workshops to NHS managers about involving families in the investigation into such events as suicides and homicides, for which I am paid expenses and an attendance fee.	2009	Jan 2022	ongoing	<i>Declare and participate, Chair, Jan 2022</i>
Stephen Habgood	Standing committee member	Non-financial personal and professional interests	Chairman of the national charity PAPYRUS Prevention of Young Suicide.	October 2011	Jan 2022	30-June 2019	<i>Declare and participate, Chair, Jan 2022</i>
Stephen Habgood	Standing committee member	Non-financial personal and professional interests	I am a lay member of the Midlands Therapeutics Review and Advisory Committee (MTRAC) After consideration of the evidence for a new medicine or existing class of medicines, the committee discusses the local use of the new medicine and agrees a set of guidance points on prescribing and commissioning issues. I have no financial interest.	2018	Jan 2022	April 2021	<i>Declare and participate, Chair, Jan 2022</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Stephen Habgood	Standing committee member	Non-financial personal and professional interests	I am on a Nice Quality Standards Advisory Committee Developing Quality Standards for the Guideline for Suicide Prevention in the Community and Custody Settings.	2018	Jan 2022	2019	<i>Declare and participate, Chair, Jan 2022</i>
Stephen Habgood	Standing committee member	Non-financial personal and professional interests	Assistant Priest – Parish of Eccleshall in the Diocese of Lichfield This is a non-stipendiary role, and I am paid fees for some services, such as funerals or weddings.	2018	Jan 2022	Ongoing	<i>Declare and participate, Chair, Jan 2022</i>
Stephen Habgood	Standing committee member	Non-financial personal and professional interests	Advisor to the Board of Trustees of the charity Survivors of Bereavement by Suicide. (SOBS)	2017	Jan 2022	April 2021	<i>Declare and participate, Chair, Jan 2022</i>
Avril McCarthy	Standing committee member	None					
Emil Lam	Standing committee member	None					
Katherine Boylan	Standing committee member	Non-financial personal and professional interests	Manchester University NHS Foundation Trust (MFT) [her employer] is part of a project (ID-LIVER) funded by Innovate UK, led by the University of Manchester, around the early detection of liver disease. Echosens is not a partner on the bid, but MFT entered into a loan agreement to get access to the Fibroscan to allow the technology to be used within the		September 2022		<i>Declare and participate, AD, September 2022</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			community liver assessment clinics that have been set up as part of the ID-LIVER project. In return, MFT will share fully anonymised scan data and basic patient demographics. There is no financial recompense or other value negotiated (in either direction) - MFT just gets use of the device.				